AKEBIA THERAPEUTICS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Revenue | $207.7M | $181.2M | $1.5M | $0 | $0 | — | — |
| Cost of Revenue | $7.8M | — | — | — | — | — | — |
| Gross Profit | $200.0M | — | — | — | — | — | — |
| Gross Margin | 96.3% | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $291.0M | $230.9M | $115.8M | $43.0M | $23.3M | $8.9M | $5.6M |
| SG&A Expense | $87.1M | $27.0M | $22.2M | $18.5M | $14.7M | $7.0M | $2.9M |
| Operating Income | $-178.2M | $-76.7M | $-136.5M | $-61.5M | $-37.9M | $-15.9M | $-8.5M |
| Operating Margin | -85.8% | -42.3% | -8,889.9% | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-171.9M | $-73.7M | $-135.7M | — | — | — | — |
| Income Tax Expense | $-28.3M | — | — | — | — | — | — |
| Net Income | $-143.6M | $-73.7M | $-135.7M | $-60.7M | $-37.0M | $-13.2M | $-8.2M |
| Net Margin | -69.1% | -40.7% | -8,843.5% | — | — | — | — |
| EPS (Basic) | $-2.47 | $-1.69 | $-3.60 | $-2.29 | $-8.04 | $-126.94 | $-27.82 |
| EPS (Diluted) | $-2.47 | $-1.69 | $-3.60 | $-2.29 | $-8.04 | $-126.94 | $-27.82 |
| Shares Outstanding (Basic) | 116.9M | 47.6M | 38.6M | 30.7M | 20.4M | 1.4M | — |
| Shares Outstanding (Diluted) | 116.9M | 47.6M | 38.6M | 30.7M | 20.4M | 1.4M | — |
| Dividends Per Share | — | — | — | — | — | — | — |